Skip to main content
SpringerLink
Log in

Personalised dosing of pembrolizumab saves costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 US dollars

References

  1. Goldstein DA, et al. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer. Journal of the National Cancer Institute 109: djx063, No. 11, 3 Jun 2017. Available from: URL: http://dx.doi.org/10.1093/jnci/djx063

    Article  Google Scholar 

  2. Bach PB, et al. Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. Internet Document 109: djx125, No. 11, 14 Jul 2017. Available from: URL: https://doi.org/10.1093/jnci/djx125

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Personalised dosing of pembrolizumab saves costs. PharmacoEcon Outcomes News 783, 28 (2017). https://doi.org/10.1007/s40274-017-4199-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4199-x

Search

Navigation